News
Displaying 301–310 of 519
-
In the Press
People with disabilities are no different from anyone else. We all have strengths and challenges, and we all seek to be fully engaged in society. Treating blind people differently, either as incapable of conducting everyday tasks in life, or conversely, acting as though our ability to conduct even the most mundane chore is remarkable can be discouraging.
-
Genetic Testing for Inherited Retinal Diseases through the Foundation’s Open Access Program
Research NewsThe benefits of genetic testing for IRD patients, how to participate in the Foundation’s Open Access program, and what to expect from the genetic testing process.
-
Foundation News
My Retina Tracker Program is the highest volume IRD genetic testing program in the U.S.
-
7th Annual Retinal Cell and Gene Therapy Innovation Summit
Foundation NewsPlease note that the seventh annual Retinal Cell and Gene Therapy Innovation Summit previously scheduled for Friday, May 1st, 2020 in Baltimore, Maryland has been cancelled.
-
VISIONS 2020 Conference registration now open
Foundation NewsThe Foundation Fighting Blindness VISIONS 2020 conference will be held on June 18-20th at the Hyatt Regency Minneapolis.
-
“It was important to me to make an everyday kid a hero”
In the PressAuthor Ben Shaberman talks to Optometry Today about how families affected by blindness helped to inspire his new novel, Retina Boy
-
AGTC Reports Positive Six-Month Results for XLRP Phase 1/2 Gene Therapy Trial
Research NewsThe company is planning a Phase 3, pivotal trial for end of 2020
-
Foundation Fighting Blindness Celebrates 15th Year of VisionWalk with New Branding
Foundation NewsThis signature fundraising event has raised more than $55 million for research leading to treatments and cures for blindness.
-
First Human Study in US for Induced Pluripotent Stem Cells to be Launched for Advanced Dry AMD
Research NewsCurrently there are no treatments for Advanced Dry AMD, also known as GA, which can lead to significant central vision loss
-
First Patient Receives ProQR’s AON Therapy in Clinical Trial for RP Caused by RHO-P23H Mutation
Research NewsThe trial becomes ProQR’s third human study for inherited retinal disease therapies
